Українська Русский English

ISSN 2522-9028 (Print)
ISSN 2522-9036 (Online)
DOI: https://doi.org/10.15407/fz

Fiziologichnyi Zhurnal

is a scientific journal issued by the

Bogomoletz Institute of Physiology
National Academy of Sciences of Ukraine

Editor-in-chief: V.F. Sagach

The journal was founded in 1955 as
1955 – 1977 "Fiziolohichnyi zhurnal" (ISSN 0015 – 3311)
1978 – 1993 "Fiziologicheskii zhurnal" (ISSN 0201 – 8489)
1994 – 2016 "Fiziolohichnyi zhurnal" (ISSN 0201 – 8489)
2017 – "Fiziolohichnyi zhurnal" (ISSN 2522-9028)

Fiziol. Zh. 2015; 61(4): 63-70


THE INFLUENCE OF PROGENITOR NEUROCELLS SUPERNATANT ON THE LYMPHOCYTES CYTOTOXIC FUNCTION IN RATS WITH GLIOMA

L.D. Liubich, N.I. Lisyany

    SI «A.P. Romodanov Institute of Neurosurgery NAMS of Ukraine”, Kyiv
DOI: https://doi.org/10.15407/fz61.04.063

Abstract

The impact of rat neurogenic progenitor cells supernatant (RPNS) on the cytotoxic function of lymphocytes in rats under conditions of physiological norm and experimentally modeled tumor (brain glioma strain 101.8) was studied. The research was carried out in animals with inoculated tumor without RPNS injection and with different regimes of RPNS injection (thrice repeated from 5th to 10th day after glioma inoculation as well as 1 week and 1 month before tumor inoculation). Comparison groups included rats without glioma who triple injected with RPNS; and intact animals (control). RPNS was received from suspension of neurogenic progenitor cells (NPC) of rat brain on 14th day of gestation and injected intraperitoneally (0,12 mg per animal). Cytotoxic function of lymphocytes of experimental rats was evaluated in MTT-colorimetric test with allogeneic glioma cells. RPNS administration increased the cytotoxic activity of lymphocytes in vitro tests with allogeneic tumor cells in intact animals (to 37-38%) as well as in rats with glioma (to 11-22%). Under the RPNS influence the life expectancy and median survival of tumor-bearing animals increased (an average of 3-4 days). RPNS input modes such as triple injection from 5th to 10th day after glioma inoculation and 1 week before inoculation were the most effective. Thus, indirect tumor-inhibiting effect under intraperitoneal RPNS administration in rats with glioma is demonstrated, which is obviously due to increased efficiency of cytotoxic function of immune cells of animals with inoculated tumor under the influence of the factors produced by NPC.

Keywords: lymphocytes cytotoxic function; glioma 101.8; progenitor neurocells supernatant.

References

  1. Lisyany NI. Immunology and immunotherapy of malignant brain gliomas. Kiev: Interservice; 2011. [Russian].
  2.  
  3. Ghosh A, Bhattacharya M, Sarkar P, Acharya S, Chaudhury S. T11 target structure exerts effector function by activating immune cells in CNS against glioma where cytokine modulation provide favorable microenvironment. Indian J Exp Biol. 2010; 48(9): 879-88.
  4.  
  5. Learn CA, Fecci PE, Schmittling RJ, Xie W, Karikari I, Mitchell DA, Archer GE, Wei Z, Dressman H, Sampson JH. Profiling of CD4+, CD8+, and CD4+CD25+ CD45RO+FoxP3+ T cells in patients with malignant glioma reveals differential expression of the immunologic transcriptome compared with T cells from healthy volunteers. Clin Cancer Res. 2006; 12(24): 7306-15. CrossRef PubMed
  6.  
  7. Huang H, Hara A, Homma T, Yonekawa Y, Ohgaki H. Altered expression of immune defense genes in pilocytic astrocytomas. J Neuropathol Exp Neurol. 2005; 64 (10): 891-901. CrossRef PubMed
  8.  
  9. Nano R, Capelli E, Facoetti A, Benericetti E. Immunobiological and experimental aspects of malignant astrocytoma. Anticancer Res.2009;29:2461-6.
  10.  
  11. Mehling M, Simon P, Mittelbronn M, Meyermann R, Ferrone S, Weller M, Wiendl H. WHO grade associated downregulation of MHC class I antigen-processing machinery components in human astrocytomas: does it reflect a potential immune escape mechanism? Acta Neuropathol. 2007; 114 (2): 111-9. CrossRef PubMed
  12.  
  13. Kren L, Muckova K, Lzicarova E, Sova M, Vybihal V, Svoboda T. Production of immune-modulatory nonclassical molecules HLA-G and HLA-E by tumor infiltrating ameboid microglia/macrophages in glioblastomas: a role in innate immunity? J Neuroimmunol. 2010; 220 (1-2): 131-5.
  14.  
  15. Kren L, Slaby O, Muckova K, Lzicarova E, Sova M, Vybihal V, Svoboda T, Fadrus P, Lakomy R, Vanhara P. Expression of immune-modulatory molecules HLA-G and HLA-E by tumor cells in glioblastomas: an unexpected prognostic significance. Neuropathology. 2011; (2): 129-34.
  16.  
  17. Achanta P, Sedora Roman NI, Qui-ones-Hinojosa A. Gliomagenesis and the use of neural stem cells in brain tumor treatment. Anticancer Agents Med Chem. 2010;10 (2): 121-30. CrossRef PubMed PubMedCentral
  18.  
  19. Bovenberg MS, Degeling MH, Tannous BA. Advances in stem cell therapy against gliomas. Trends Mol Med. 2013; 19 (5): 281-91. CrossRef PubMed
  20.  
  21. Kim SU. Neural stem cell-based gene therapy for brain tumors. Stem Cell Rev. 2011; 7(1): 130-40. CrossRef PubMed
  22.  
  23. Ahmed AU, Ulasov IV, Mercer RW, Lesniak MS. Maintaining and loading neural stem cells for delivery of oncolytic adenovirus to brain tumors. Methods Mol Biol. 2012; 797: 97-109. CrossRef PubMed
  24.  
  25. Staflin K, Lindvall M, Zuchner T, Lundberg C. Instructive cross-talk between neural progenitor cells and gliomas. J Neurosci.Res. 2007; 85(10): 2147-59.
  26.  
  27. Halanskij AS, Kondakova LI, Avcyn AP. New transplantable rat brain gliomas. Voprosy nejrohirurgii.1995; (2): 23-5. [Russian].
  28.  
  29. Liubich LD, Lisyany NI, inventor; SI "Institute of neurosurgery n.acad.A.Romodanov NAMS of Ukraine", assignee. Method of study of allocytotoxic activity of immune cells. Ukraine patent UA 75059. 2012 Nov 11. [Ukrainian].
  30.  
  31. Chen HC, Ma HI, Sytwu HK, Wang HW, Chen CC, Liu SC, Chen CH, Chen HK, Wang CH. Neural stem cells secrete factors that promote auditory cell proliferation via a leukemia inhibitory factor signaling pathway. J Neurosci Res. 2010; 88(15): 3308-18. CrossRef PubMed
  32.  
  33. Klassen HJ, Imfeld KL, Kirov II, Tai L, Gage FH, Young MJ, Berman MA. Expression of cytokines by multipotent neural progenitor cells. Cytokine. 2003; 22(3-4): 101-6.
  34.  
  35. Liu J, Götherström C, Forsberg M, Samuelsson EB, Wu J, Calzarossa C, Hovatta O, Sundström E, Åkesson E. Human neural stem/progenitor cells derived from embryonic stem cells and fetal nervous system present differences in immunogenicity and immunomodulatory potentials in vitro. Stem Cell Res. 2013; 10(3): 325-37. CrossRef PubMed
  36.  
  37. Ehtesham M, Kabos P, Kabosova A, Neuman T, Black KL, Yu JS. The use of interleukin 12-secreting neural stem cells for the treatment of intracranial glioma. Cancer Res. 2002; 62(20): 5657-63.
  38.  
  39. Yang SY, Liu H, Zhang JN. Gene therapy of rat malignant gliomas using neural stem cells expressing IL-12. DNA Cell Biol. 2004; 23(6): 381-9. CrossRef PubMed
  40.  
  41. Yuan X, Hu J, Belladonna ML, Black KL, Yu JS. Interleukin-23-expressing bone-marrow-derived neural stem-like cells exhibit antitumor activity against intracranial glioma. Cancer Res. 2006; 66(5): 2630-8. CrossRef PubMed
  42.  
  43. Miwa N., Mizuno S., Suitani Y. Tumor growth-inhibitory glycoprotein secreted from the mouse brain at terminal stage of the ontogeny: molecular homogeneity and requirement of the retained protein conformation for exhibition of the cytotoxic action. Biochim.Biophys. Acta. 1990; 1034(3): 309-17
  44.  

© National Academy of Sciences of Ukraine, Bogomoletz Institute of Physiology, 2014-2019.